research

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer

Authors
Publication date
1 January 2017
Publisher
Digital Commons@Becker

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Digital Commons@Becker

    redirect
    oaioai:digitalcommons.wustl.edu:o...
    Last time updated on 09/07/2019